Solid Biosciences receives FDA Fast Track designation for SGT-003

Solid Biosciences announced that it has received Fast Track Designation from the U.S. Food and Drug Administration, FDA, for SGT-003, the company’s next-generation Duchenne muscular dystrophy gene therapy candidate. “Receipt of FDA Fast Track Designation underscores the importance of rapidly developing SGT-003 to potentially aid the unmet needs of the Duchenne community,” said Bo Cumbo, President and CEO at Solid Biosciences. “Having received IND clearance for SGT-003 last month, we are pleased to be expediting the development of a potentially life-changing therapy and look forward to continuing to work closely with the FDA.”